A citation-based method for searching scientific literature


List of co-cited articles
341 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
26

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
23

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
19

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto, Takanori Tomotsune, Kazunori Yanagi, Toshie Iijima, Kunihiro Suzuki, Kikuo Kasai, Yoshimasa Aso. Atherosclerosis 2017
59
17


Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
839
15

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.
Hiromasa Goto, Takashi Nomiyama, Tomoya Mita, Eisuke Yasunari, Kosuke Azuma, Koji Komiya, Masayuki Arakawa, Wen Long Jin, Akio Kanazawa, Ryuzo Kawamori,[...]. Biochem Biophys Res Commun 2011
89
13

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
460
13

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
385
13

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Tracey Gaspari, HongBin Liu, Iresha Welungoda, Yunshan Hu, Robert E Widdop, Lotte B Knudsen, Richard W Simpson, Anthony E Dear. Diab Vasc Dis Res 2011
129
13

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
13


Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.
Yoichiro Hirata, Hirotsugu Kurobe, Chika Nishio, Kimie Tanaka, Daiju Fukuda, Etsuko Uematsu, Sachiko Nishimoto, Takeshi Soeki, Nagakatsu Harada, Hiroshi Sakaue,[...]. Eur J Pharmacol 2013
38
15


Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.
Kosuke Nagayama, Yoji Kyotani, Jing Zhao, Satoyasu Ito, Kentaro Ozawa, Francesco A Bolstad, Masanori Yoshizumi. PLoS One 2015
40
15


A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Yuko Tashiro, Kengo Sato, Takuya Watanabe, Kyoko Nohtomi, Michishige Terasaki, Masaharu Nagashima, Tsutomu Hirano. Peptides 2014
72
11

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, Ib Klewe, Klaus S Frederiksen, Robert Augustin, Jacob Hecksher-Sørensen, Camilla Ingvorsen, Joseph Polex-Wolf, Lotte Bjerre Knudsen. JACC Basic Transl Sci 2018
148
11

Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.
Johanna Helmstädter, Katie Frenis, Konstantina Filippou, Alexandra Grill, Mobin Dib, Sanela Kalinovic, Franziska Pawelke, Kamil Kus, Swenja Kröller-Schön, Matthias Oelze,[...]. Arterioscler Thromb Vasc Biol 2020
80
11

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
11

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Kiwon Ban, Kyoung-Han Kim, Chan-Kyung Cho, Meghan Sauvé, Eleftherios P Diamandis, Peter H Backx, Daniel J Drucker, Mansoor Husain. Endocrinology 2010
168
9

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
772
9

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Hisko Oeseburg, Rudolf A de Boer, Hendrik Buikema, Pim van der Harst, Wiek H van Gilst, Herman H W Silljé. Arterioscler Thromb Vasc Biol 2010
195
9

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
328
9

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.
Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takeya. Biochem Biophys Res Commun 2012
107
9

GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.
Bruno Schisano, Alison L Harte, Konstantinos Lois, Ponnusamy Saravanan, Nasser Al-Daghri, Omar Al-Attas, Lotte B Knudsen, Philip G McTernan, Antonio Ceriello, Gyanendra Tripathi. Regul Pept 2012
66
9

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
858
9


Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
Juraj Koska, Michelle Sands, Camelia Burciu, Karen M D'Souza, Kalyani Raravikar, James Liu, Seth Truran, Daniel A Franco, Eric A Schwartz, Dawn C Schwenke,[...]. Diabetes 2015
87
9


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
9

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
619
9

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
7


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
7

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.
Hari Hendarto, Toyoshi Inoguchi, Yasutaka Maeda, Noriko Ikeda, Jing Zheng, Ryoko Takei, Hisashi Yokomizo, Eiichi Hirata, Noriyuki Sonoda, Ryoichi Takayanagi. Metabolism 2012
152
7


The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
7


Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
298
7

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.
M Nagashima, T Watanabe, M Terasaki, M Tomoyasu, K Nohtomi, J Kim-Kaneyama, A Miyazaki, T Hirano. Diabetologia 2011
175
7

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
419
7

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
William R Hiatt, Sanjay Kaul, Robert J Smith. N Engl J Med 2013
132
7


Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
7


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
7

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
7

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
Andrew E Hogan, Gadintshware Gaoatswe, Lydia Lynch, Michelle A Corrigan, Conor Woods, Jean O'Connell, Donal O'Shea. Diabetologia 2014
112
7

Recent updates on GLP-1 agonists: Current advancements & challenges.
Dilip Sharma, Suril Verma, Shivani Vaidya, Kiran Kalia, Vinod Tiwari. Biomed Pharmacother 2018
104
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.